Avapritinib companion diagnostic - CStone Pharmaceuticals/Genetron Health
Latest Information Update: 28 Oct 2023
At a glance
- Originator CStone Pharmaceuticals; Genetron Health
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Gastrointestinal stromal tumours
Most Recent Events
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in Gastrointestinal-stromal-tumours(Diagnosis) in China
- 25 Sep 2020 CStone Pharmaceuticals and Genetron Health enter into a collaboration for the development and commercialization of avapritinib companion diagnostic in Greater China
- 25 Sep 2020 Clinical trials in Gastrointestinal stromal tumours (Diagnosis) in China